放疗联合免疫检查点抑制剂在非小细胞肺癌中的临床研究进展  

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC

作　　者：朱魁魁 伍钢[1] ZHU Kuikui;WU Gang(Cancer Center,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022

出　　处：《肿瘤防治研究》2021年第10期916-921,共6页Cancer Research on Prevention and Treatment

摘　　要：肺癌是癌症相关死亡病因最高的恶性肿瘤,其中非小细胞肺癌(NSCLC)约占所有肺癌的85%,超过50%的NSCLC患者确诊时伴有远处转移。NSCLC的综合治疗需要采用手术、放疗、化疗、靶向治疗及免疫检查点抑制剂等方式。放疗作为传统治疗手段之一,在各期NSCLC的治疗中均发挥着重要作用,其免疫调节效应备受关注;免疫检查点抑制剂(ICIs)的应用显著改善了晚期和局部晚期NSCLC患者的预后,但获益人群有限。目前放疗联合ICIs的治疗模式成为研究热点,本文就放疗联合ICIs在NSCLC治疗中的研究进展作一综述。Lung cancer is the leading cause of cancer-related deaths across the world,of which non-small cell lung cancer(NSCLC)accounts for 85%,and more than 50%of NSCLC patients were diagnosed with distant metastasis.The comprehensive treatment of NSCLC includes surgery,radiotherapy,chemotherapy,targeted therapy and immune checkpoint inhibitors.As one of the traditional treatment methods,radiotherapy plays an important role in the treatment of all stages of NSCLC,and its immunomodulatory effect has attracted much attention.The application of immune checkpoint inhibitors(ICIs)has significantly improved the prognosis of patients with local-advanced and advanced NSCLC,but the benefit population was limited.At present,the treatment mode of radiotherapy combined with ICIs has become the focus of research.This paper reviews the research progress of radiotherapy combined with ICIs in the treatment of NSCLC.

关 键 词：非小细胞肺癌 放射治疗 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]